Digital Biomarkers Solution Shows Pathway To Reduced Clinical Trial Sample Sizes, Shorter Durations

Digital biomarkers offer a promising pathway to the future, benefiting both clinical trial sponsors and patients. The Roche Digital Biomarkers Solution has demonstrated preliminary reliability and validity in the remote at-home collection of motor sign severity in patients with early Parkinson’s disease.

Evidence from this simulated trial indicates that using digital biomarkers, where the motor score served as the primary endpoint over the traditional Unified Parkinson’s Disease Rating Scale (UPDRS), has the potential to reduce trial sample sizes by approximately 70% and shorten trial durations by 16 months. This significant reduction in sample size and trial duration could lower overall trial costs and accelerate the pace of innovation in Parkinson’s disease treatment.

Download a copy of the results from our simulated study below to learn more about these benefits.